XML 22 R13.htm IDEA: XBRL DOCUMENT v3.23.2

Accrued Expenses

6 Months Ended

Jun. 30, 2023

Payables and Accruals [Abstract]

Accrued Expenses

Accrued ExpensesAccrued expenses consisted of the following (in thousands):

			June 30, 2023						December 31, 2022
Accrued external research and development expenses			$	3,972					$	10,734
Accrued milestone expense			6,937						—
Accrued personnel-related expenses			1,617						2,803
Accrued other expenses			791						2,313
Total accrued expenses			$	13,317					$	15,850

At June 30, 2023, accrued expenses included $6.9 million of milestone expense related to the Research Collaboration, Option and License Agreement between the Company and Ionis Pharmaceuticals, Inc., earned upon initiation of the Company's PRAX-222 EMBRAVE study in the second quarter of 2023. The milestone was paid in July 2023.

X

- Definition

The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19(a),20,24)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1

+ Details

Name:	us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_PayablesAndAccrualsAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration